Answer
After brexucabtagene autoleucel (Tecartus) engages CD19-expressing target cells, the CD28 co-stimulatory domain and CD3-zeta signalling domain activate downstream signalling cascades leading to T-cell activation.
Sources for this answer
- TecartusGilead Sciences Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked